Physician profile
Jerry N Bean
NPI 1750497574
$1,313.75
in general payments reported to CMS, 2019-2025
13 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.34 · 2020: $391 · 2021: $188 · 2022: $189 · 2023: $217 · 2024: $47.98 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $380.74 | 2021-2025 | Vraylar |
| Pfizer INC. | $246.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $144.93 | 2019-2024 | |
| Lilly USA, LLC | $141.02 | 2020-2023 | Mounjaro |
| Novo Nordisk INC | $125.50 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.39 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.12 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $43.29 | 2021-2022 | |
| Glaxosmithkline, LLC. | $26.90 | 2020 | |
| Sunovion Pharmaceuticals INC. | $20.31 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.84 | 2025 | Caplyta |
| Amgen INC. | $13.41 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.35 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.